ro4402257
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2000 (NCT00686010)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- MAP kinase p38 betaINHIBITOR
MAPK11 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21- Mol. weight
- 406.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1090089 ↗
Also known as
- jtt705
- jtt 705
- jtt-705
- jtt-705
- jtt-705
- pamapimod
- pamapimod
- r-1503
- r-1503
- ro4402257
- ro4402257
- ro-4402257
- ro-4402257
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05659459 | Phase 2 | Aug 25, 2022 | Kinarus AG |
| NCT00303563 | Phase 2 | Apr 1, 2006 | Roche |
| NCT00316771 | Phase 2 | Nov 1, 2005 | Roche |
| NCT00688558 | Phase 2 | Feb 1, 2004 | Akros |
| NCT00689442 | Phase 2 | Jan 1, 2004 | Akros |
| NCT00688896 | Phase 2 | Jun 1, 2002 | Akros |
| NCT00686010 | Phase 2 | May 1, 2000 | Japan Tobacco Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akros | For profit | 3 | 3 | 1 | 2002 |
| Roche | For profit | 2 | 2 | 1 | 2005 |
| Japan Tobacco Inc. | For profit | 1 | 1 | 1 | 2000 |
| Kinarus AG | For profit | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1